Research Analysts Offer Predictions for ARWR FY2026 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biotechnology company will earn ($4.72) per share for the year. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share.

Several other analysts have also commented on the stock. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. B. Riley reiterated a "buy" rating and issued a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.71.

Arrowhead Pharmaceuticals Price Performance

ARWR traded down $0.48 on Wednesday, hitting $15.74. 1,219,107 shares of the company were exchanged, compared to its average volume of 1,531,912. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The business's fifty day moving average is $14.25 and its 200 day moving average is $17.19. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $30.41. The firm has a market capitalization of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.96.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its stake in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,628 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $49,000. Van ECK Associates Corp grew its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 1,250 shares in the last quarter. CWM LLC grew its holdings in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 2,523 shares in the last quarter. Finally, KBC Group NV grew its holdings in Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 2,132 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the transaction, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.